Esbriet

Active Ingredient(s): Pirfenidone
FDA Approved: * October 15, 2014
Pharm Company: * INTERMUNE INC
Category: Lungs (Pulmonary)

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Esbriet Overview

Pirfenidone is a medication used for the treatment of idiopathic pulmonary fibrosis. It works by reducing lung fibrosis through downregulation of the production of growth factors and procollagens I and II. It was developed by several companies worldwide, including the original patent holder, Marnac,[2] InterMune Inc. (now part of Roche), Shionogi Ltd., and GNI Group Ltd. In 2008, it was first approved in Japan for the treatment of patients with idiopathic pulmonary fibrosis af...

Read more Esbriet Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Pirfenidone

Recent Esbriet Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Pirfenidone
  • Capsule: 267mg
  • Tablet: 267mg, 534mg, 801mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Esbriet: (4 results)

Sorted by National Drug Code
  • 50242-121 Esbriet 267 mg Oral Capsule by Genentech, Inc.
  • 50242-122 Esbriet 267 mg Oral Tablet, Coated by Genentech, Inc.
  • 50242-123 Esbriet 801 mg Oral Tablet, Coated by Genentech, Inc.
  • 64116-121 Esbriet 267 mg Oral Capsule by Intermune, Inc.

Other drugs which contain Pirfenidone or a similar ingredient: (1 result)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 23 September 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA